ALTAMIRA THERAPEUTICS LTD (CYTO) Fundamental Analysis & Valuation

NASDAQ:CYTO • BMG0360L1349

Current stock price

0.3 USD
-0.11 (-25.94%)
At close:
0.262 USD
-0.04 (-12.67%)
After Hours:

This CYTO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. CYTO Profitability Analysis

1.1 Basic Checks

  • In the past year CYTO was profitable.
  • CYTO had a positive operating cash flow in the past year.
  • In the past 5 years CYTO always reported negative net income.
  • CYTO had a negative operating cash flow in each of the past 5 years.
CYTO Yearly Net Income VS EBIT VS OCF VS FCFCYTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of CYTO (-0.09%) is better than 82.20% of its industry peers.
  • CYTO has a better Return On Equity (-0.11%) than 82.72% of its industry peers.
Industry RankSector Rank
ROA -0.09%
ROE -0.11%
ROIC N/A
ROA(3y)-179.21%
ROA(5y)-129.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTO Yearly ROA, ROE, ROICCYTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CYTO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTO Yearly Profit, Operating, Gross MarginsCYTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CYTO Health Analysis

2.1 Basic Checks

  • CYTO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CYTO has been increased compared to 1 year ago.
  • CYTO has a better debt/assets ratio than last year.
CYTO Yearly Shares OutstandingCYTO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M
CYTO Yearly Total Debt VS Total AssetsCYTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

  • CYTO has an Altman-Z score of 1.19. This is a bad value and indicates that CYTO is not financially healthy and even has some risk of bankruptcy.
  • CYTO's Altman-Z score of 1.19 is fine compared to the rest of the industry. CYTO outperforms 60.21% of its industry peers.
  • CYTO has a debt to FCF ratio of 0.09. This is a very positive value and a sign of high solvency as it would only need 0.09 years to pay back of all of its debts.
  • CYTO's Debt to FCF ratio of 0.09 is amongst the best of the industry. CYTO outperforms 96.86% of its industry peers.
  • A Debt/Equity ratio of 0.05 indicates that CYTO is not too dependend on debt financing.
  • The Debt to Equity ratio of CYTO (0.05) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.09
Altman-Z 1.19
ROIC/WACCN/A
WACC7.3%
CYTO Yearly LT Debt VS Equity VS FCFCYTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

  • A Current Ratio of 0.43 indicates that CYTO may have some problems paying its short term obligations.
  • CYTO's Current ratio of 0.43 is on the low side compared to the rest of the industry. CYTO is outperformed by 95.81% of its industry peers.
  • CYTO has a Quick Ratio of 0.43. This is a bad value and indicates that CYTO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of CYTO (0.43) is worse than 95.29% of its industry peers.
Industry RankSector Rank
Current Ratio 0.43
Quick Ratio 0.43
CYTO Yearly Current Assets VS Current LiabilitesCYTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CYTO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 101.44% over the past year.
  • CYTO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -79.76%.
EPS 1Y (TTM)101.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.56%
Revenue 1Y (TTM)-79.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CYTO will show a decrease in Earnings Per Share. The EPS will decrease by -4.65% on average per year.
  • Based on estimates for the next years, CYTO will show a very strong growth in Revenue. The Revenue will grow by 214.13% on average per year.
EPS Next Y-88.67%
EPS Next 2Y8.03%
EPS Next 3Y-4.65%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y214.13%
Revenue Next 5YN/A

3.3 Evolution

CYTO Yearly Revenue VS EstimatesCYTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2026 1M 2M 3M 4M 5M
CYTO Yearly EPS VS EstimatesCYTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2024 2025 2026 -1K -2K -3K -4K

More info and screens

Find the best growth stocksShow best growing peers

4

4. CYTO Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 0.36 indicates a rather cheap valuation of CYTO.
  • Compared to the rest of the industry, the Price/Earnings ratio of CYTO indicates a rather cheap valuation: CYTO is cheaper than 99.48% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.96. CYTO is valued rather cheaply when compared to this.
  • CYTO is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 0.36
Fwd PE N/A
CYTO Price Earnings VS Forward Price EarningsCYTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CYTO indicates a rather cheap valuation: CYTO is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 0.25
EV/EBITDA N/A
CYTO Per share dataCYTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

  • CYTO's earnings are expected to decrease with -4.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.03%
EPS Next 3Y-4.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CYTO Dividend Analysis

5.1 Amount

  • CYTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CYTO Fundamentals: All Metrics, Ratios and Statistics

ALTAMIRA THERAPEUTICS LTD

NASDAQ:CYTO (12/19/2024, 10:21:17 PM)

After market: 0.262 -0.04 (-12.67%)

0.3

-0.11 (-25.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-10
Earnings (Next)N/A
Inst Owners0.13%
Inst Owner Change0%
Ins Owners0.53%
Ins Owner ChangeN/A
Market Cap1.13M
Revenue(TTM)62.75K
Net Income(TTM)-7.24K
Analysts82.86
Price Target5.41 (1703.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-35.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)31.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.36
Fwd PE N/A
P/S 18.07
P/FCF 0.25
P/OCF 0.25
P/B 0.18
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)0.83
EY276.67%
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)1.22
FCFY406.8%
OCF(TTM)1.22
OCFY406.8%
SpS0.02
BVpS1.67
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.09%
ROE -0.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 7351.86%
ROA(3y)-179.21%
ROA(5y)-129.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.09
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.43
Quick Ratio 0.43
Altman-Z 1.19
F-Score6
WACC7.3%
ROIC/WACCN/A
Cap/Depr(3y)1981.94%
Cap/Depr(5y)5522.5%
Cap/Sales(3y)2080.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)101.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.56%
EPS Next Y-88.67%
EPS Next 2Y8.03%
EPS Next 3Y-4.65%
EPS Next 5YN/A
Revenue 1Y (TTM)-79.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y214.13%
Revenue Next 5YN/A
EBIT growth 1Y98.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y126.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y132.19%
OCF growth 3YN/A
OCF growth 5YN/A

ALTAMIRA THERAPEUTICS LTD / CYTO Fundamental Analysis FAQ

What is the fundamental rating for CYTO stock?

ChartMill assigns a fundamental rating of 3 / 10 to CYTO.


Can you provide the valuation status for ALTAMIRA THERAPEUTICS LTD?

ChartMill assigns a valuation rating of 4 / 10 to ALTAMIRA THERAPEUTICS LTD (CYTO). This can be considered as Fairly Valued.


What is the profitability of CYTO stock?

ALTAMIRA THERAPEUTICS LTD (CYTO) has a profitability rating of 2 / 10.


What is the valuation of ALTAMIRA THERAPEUTICS LTD based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ALTAMIRA THERAPEUTICS LTD (CYTO) is 0.36 and the Price/Book (PB) ratio is 0.18.


What is the financial health of ALTAMIRA THERAPEUTICS LTD (CYTO) stock?

The financial health rating of ALTAMIRA THERAPEUTICS LTD (CYTO) is 3 / 10.